Global funding of Innovation for Neglected Diseases (G-FINDER)

Dr Javier Guzman
Director of Research
jguzman@policycures.org
G-FINDER
SCOPE

How much funding is being invested into neglected disease R&D globally?

- Funded by the Bill & Melinda Gates Foundation
- 5 data points (FY2007-FY2011)
- Just funded for 3 additional years (FY2012-FY2014)
G-FINDER
SCOPE

- 31 neglected diseases
- 134 product areas (drugs, vaccines, diagnostics, microbicides and vector control products)
- Platform technologies (adjuvants, delivery technologies, diagnostic platforms)
- All types of product-related R&D
G-FINDER
SURVEY PARTICIPANTS

240 Orgs

By org type
- Public sector (126 orgs)
- Philanthropic sector (21 orgs)
- Private sector (70 orgs)
- Other
  - Product Development Partnerships (17 orgs)
  - Other intermediary organisations (6 orgs)

By location
- High Income Countries
- Low and Middle Income Countries
- Brazil, India, South Africa
**G-FINDER**

### Strengths

- Accurate, consistent up-to-date financial information on funders, developers, diseases, product disease areas, stages of development
- Excellent map of stakeholders involved in funding and conducting ND R&D
- Widely recognized and available resource
- Only primary data

### Limitations

- Resource intensive
- Narrow scope
- Focuses on R&D inputs without considering R&D outputs
- Time-lag between funding info and R&D decisions
- Aggregate industry figures and CDAs
G-FINDER OPPORTUNITIES

- Scope expansion
- New IT systems and processes
- Additional value-add materials
- Linkage with other tracking efforts
Download the full report at

www.policycures.org/g-finder2012.html